Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Genmab A/s LSE:0MGB London Ordinary Share DK0010272202 GENMAB ORD SHS
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  6.75 0.49% 1,381.50 1,351.50 1,411.50 1,381.50 1,381.50 1,381.50 7,533 08:00:02
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
- - - - 0

Genmab A/S Constitution Of The Board Of Directors In Genmab A/S, Grant Of Restricted Stock Units To The New Member Of The Boa...

26/03/2020 7:54pm

UK Regulatory (RNS & others)


 
TIDMGEN 
 
 
   Company Announcement 
 
   Copenhagen, Denmark; March 26, 2020 -- Following Genmab A/S' (Nasdaq: 
GMAB) Annual General Meeting held on March 26, 2020, the Company's Board 
of Directors met to constitute itself. Ms. Deirdre P. Connelly was 
appointed Chairman and Ms. Pernille Erenbjerg was appointed Deputy 
Chairman. It was decided to grant 17,690 restricted stock units to the 
new member of the Board of Directors, the two new members of Management 
and employees of the Company and three of the Company's subsidiaries and 
33,678 warrants to one of the new members of Management and employees of 
the Company and three of the Company's subsidiaries. 
 
   Each restricted stock unit is awarded cost-free and provides the owner 
with a right and obligation to receive one share in Genmab A/S of 
nominally DKK 1. The vesting of the restricted stock units granted to 
the two new members of Management will be subject to forward looking 
performance criteria. The fair value of each restricted stock unit is 
equal to the closing market price on the date of grant of one Genmab A/S 
share, DKK 1,362.50. 
 
   The restricted stock units will vest on the first banking day of the 
month following a period of three years from the date of grant. 
Furthermore, the restricted stock units are subject to vesting 
conditions set out in the restricted stock unit program adopted by the 
Board of Directors and in accordance with the Remuneration Policy 
adopted by the shareholders at the annual general meeting. Information 
concerning Genmab's restricted stock unit program can be found on 
https://www.globenewswire.com/Tracker?data=8T9xBkuJYil99CSFhHDZuw8WsoDLBXZ3PDpT2imHHS86FpwUrv3EUN9d4n2-BDIQcdaAX9HNx2C0LhrJp7uH9Q== 
www.genmab.com under Investors > Stock information > Restricted stock 
units. 
 
   The exercise price for each warrant is DKK 1,362.50. Each warrant is 
awarded cost-free and entitles the owner to subscribe one share of 
nominally DKK 1 subject to payment of the exercise price. By application 
of the Black-Scholes formula, the fair value of each warrant can be 
calculated as DKK 393.72. 
 
   The warrants vest three years after the grant date, and all warrants 
expire at the seventh anniversary of the grant date. The new warrants 
have been granted on the terms and conditions set out in the warrant 
program adopted by the Board of Directors on March 28, 2017. Information 
concerning Genmab's warrant schemes can be found on 
https://www.globenewswire.com/Tracker?data=8T9xBkuJYil99CSFhHDZu_K76qgu_q4oKeBpUQ6sD37CvFz17oqncHLDW9PA0P3HQyb68-6_5TEg6z6I8mLEQw== 
www.genmab.com under Investors > Stock information > Warrants. 
 
   About Genmab 
 
   Genmab is a publicly traded, international biotechnology company 
specializing in the creation and development of differentiated antibody 
therapeutics for the treatment of cancer. Founded in 1999, the company 
is the creator of three approved antibodies: DARZALEX(R) (daratumumab, 
under agreement with Janssen Biotech, Inc.) for the treatment of certain 
multiple myeloma indications in territories including the U.S., Europe 
and Japan, Arzerra(R) (ofatumumab, under agreement with Novartis AG), 
for the treatment of certain chronic lymphocytic leukemia indications in 
the U.S., Japan and certain other territories and TEPEZZA(TM) 
(teprotumumab, under agreement with Roche granting sublicense to Horizon 
Therapeutics plc) for the treatment of thyroid eye disease in the U.S. 
Daratumumab is in clinical development by Janssen for the treatment of 
additional multiple myeloma indications, other blood cancers and 
amyloidosis. A subcutaneous formulation of ofatumumab is in development 
by Novartis for the treatment of relapsing multiple sclerosis. Genmab 
also has a broad clinical and pre-clinical product pipeline. Genmab's 
technology base consists of validated and proprietary next generation 
antibody technologies - the DuoBody(R) platform for generation of 
bispecific antibodies, the HexaBody(R) platform, which creates effector 
function enhanced antibodies, the HexElect(R) platform, which combines 
two co-dependently acting HexaBody molecules to introduce selectivity 
while maximizing therapeutic potency and the DuoHexaBody(R) platform, 
which enhances the potential potency of bispecific antibodies through 
hexamerization. The company intends to leverage these technologies to 
create opportunities for full or co-ownership of future products. Genmab 
has alliances with top tier pharmaceutical and biotechnology companies. 
Genmab is headquartered in Copenhagen, Denmark with sites in Utrecht, 
the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. 
 
   Contact: 
 
   Marisol Peron, Corporate Vice President, Communications & Investor 
Relations 
 
   T: +1 609 524 0065; E: 
https://www.globenewswire.com/Tracker?data=WwHA7F8vnyDvWSK_LRn8nJY2tmEbDsjfb-p7f_4anRG8VC54TyR3Xbsfk2FE56dhfPI4bOnvt28eaMUuYNZl1A== 
mmp@genmab.com 
 
   For Investor Relations: 
 
   Andrew Carlsen, Senior Director, Investor Relations 
 
   T: +45 3377 9558; E: 
https://www.globenewswire.com/Tracker?data=dLxk3gjXA5JLpOzwNKt5eNyHHmwuHFZVKjU_Yx9RCf6qpmcbmaKFwWgotKJkL3rW7y8VUpxkuELJqSTBZIpEOw== 
acn@genmab.com 
 
   This Company Announcement contains forward looking statements. The words 
"believe", "expect", "anticipate", "intend" and "plan" and similar 
expressions identify forward looking statements. Actual results or 
performance may differ materially from any future results or performance 
expressed or implied by such statements. The important factors that 
could cause our actual results or performance to differ materially 
include, among others, risks associated with pre-clinical and clinical 
development of products, uncertainties related to the outcome and 
conduct of clinical trials including unforeseen safety issues, 
uncertainties related to product manufacturing, the lack of market 
acceptance of our products, our inability to manage growth, the 
competitive environment in relation to our business area and markets, 
our inability to attract and retain suitably qualified personnel, the 
unenforceability or lack of protection of our patents and proprietary 
rights, our relationships with affiliated entities, changes and 
developments in technology which may render our products or technologies 
obsolete, and other factors. For a further discussion of these risks, 
please refer to the risk management sections in Genmab's most recent 
financial reports, which are available on 
https://www.globenewswire.com/Tracker?data=8T9xBkuJYil99CSFhHDZu_-cb9E3t9Y3Zj3_ukGlI3VA5HxepWxAyALIP-jJS_EMOVXVe6vrsteJrxIGrxznVg== 
www.genmab.com and the risk factors included in Genmab's final 
prospectus for our U.S. public offering and listing and other filings 
with the U.S. Securities and Exchange Commission (SEC), which are 
available at 
https://www.globenewswire.com/Tracker?data=8T9xBkuJYil99CSFhHDZu7H7B3RdZXurktpPpE5t6C217KaQOrwt-n88fqh83VYQCMdQ0XDlpSO_grfLs3VUvBCj2pjiPOueEKUpJYj3oXk= 
www.sec.gov. Genmab does not undertake any obligation to update or 
revise forward looking statements in this Company Announcement nor to 
confirm such statements to reflect subsequent events or circumstances 
after the date made or in relation to actual results, unless required by 
law. 
 
   Genmab A/S and/or its subsidiaries own the following trademarks: 
Genmab(R) ; the Y-shaped Genmab logo(R) ; Genmab in combination with the 
Y-shaped Genmab logo(R) ; HuMax(R) ; DuoBody(R) ; DuoBody in combination 
with the DuoBody logo(R) ; HexaBody(R) ; HexaBody in combination with 
the HexaBody logo(R) ; DuoHexaBody(R) ; HexElect(R) ; and UniBody(R) . 
Arzerra(R) is a trademark of Novartis AG or its affiliates. DARZALEX(R) 
is a trademark of Janssen Pharmaceutica NV. TEPEZZA(TM) is a trademark 
of Horizon Therapeutics plc. 
 
 
 
 
 
   Company Announcement no. 13 
 
   CVR no. 2102 3884 
 
   LEI Code 529900MTJPDPE4MHJ122 
 
   Genmab A/S 
 
   Kalvebod Brygge 43 
 
   1560 Copenhagen V 
 
   Denmark 
 
   Attachment 
 
 
   -- 260320_CA13_Constitution of the Board and grant of RSUs and Warrants 
      https://ml-eu.globenewswire.com/Resource/Download/5bdf846f-46b2-4af2-be9f-5c4824feac23 
 
 
 
 
 
 
 

(END) Dow Jones Newswires

March 26, 2020 15:54 ET (19:54 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

1 Year Genmab A/s Chart

1 Year Genmab A/s Chart

1 Month Genmab A/s Chart

1 Month Genmab A/s Chart
ADVFN Advertorial
Your Recent History
LSE
0MGB
Genmab A/s
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20200404 11:17:39